HRP20160646T1 - Poboljšano liječenje multiplog mijeloma - Google Patents

Poboljšano liječenje multiplog mijeloma Download PDF

Info

Publication number
HRP20160646T1
HRP20160646T1 HRP20160646TT HRP20160646T HRP20160646T1 HR P20160646 T1 HRP20160646 T1 HR P20160646T1 HR P20160646T T HRP20160646T T HR P20160646TT HR P20160646 T HRP20160646 T HR P20160646T HR P20160646 T1 HRP20160646 T1 HR P20160646T1
Authority
HR
Croatia
Prior art keywords
aplidine
dexamethasone
multiple myeloma
improved treatment
use according
Prior art date
Application number
HRP20160646TT
Other languages
English (en)
Inventor
Glynn Thomas Faircloth
Pablo Manuel Aviles Marin
Doreen Lepage
Jesus San Miguel Izquierdo
Atanasio Pandiella
Original Assignee
Pharma Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar, S.A. filed Critical Pharma Mar, S.A.
Publication of HRP20160646T1 publication Critical patent/HRP20160646T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (4)

1. Aplidin za primjenu u metodi za liječenje multiplog mijeloma pomoću kombinirane terapije korištenjem Aplidina u sinergističkoj kombinaciji sa deksametazonom.
2. Aplidin za primjenu prema patentnom zahtjevu 1, gdje Aplidin i deksametazon formiraju dio iste kompozicije.
3. Aplidin za primjenu prema patentnom zahtjevu 1, gdje su Aplidin i deksametazon osigurani kao zasebne kompozicije gdje je deksametazon administriran prije, za vrijeme, ili nakon administriranja Aplidina.
4. Aplidin za primjenu prema patentnom zahtjevu 3, gdje su Aplidin i deksametazon osigurani kao zasebne kompozicije u kojima je deksametazon administriran prije, ili nakon administriranja Aplidina.
HRP20160646TT 2006-02-28 2016-06-10 Poboljšano liječenje multiplog mijeloma HRP20160646T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81360606P 2006-02-28 2006-02-28
EP07757603.1A EP2029155B1 (en) 2006-02-28 2007-02-28 Improved treatment of multiple myeloma
PCT/US2007/062936 WO2007101235A2 (en) 2006-02-28 2007-02-28 Improved antitumoral treatments

Publications (1)

Publication Number Publication Date
HRP20160646T1 true HRP20160646T1 (hr) 2016-08-12

Family

ID=38459806

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160646TT HRP20160646T1 (hr) 2006-02-28 2016-06-10 Poboljšano liječenje multiplog mijeloma

Country Status (24)

Country Link
US (1) US8258098B2 (hr)
EP (1) EP2029155B1 (hr)
JP (2) JP5393159B2 (hr)
KR (2) KR101512503B1 (hr)
CN (1) CN101389347B (hr)
AU (1) AU2007220050B2 (hr)
CA (1) CA2643238C (hr)
CY (1) CY1117722T1 (hr)
DK (1) DK2029155T3 (hr)
ES (1) ES2575518T3 (hr)
HK (1) HK1127294A1 (hr)
HR (1) HRP20160646T1 (hr)
HU (1) HUE028055T2 (hr)
IL (1) IL193094A (hr)
ME (1) ME02450B (hr)
MX (1) MX2008010999A (hr)
NO (1) NO342012B1 (hr)
NZ (1) NZ571043A (hr)
PL (1) PL2029155T3 (hr)
PT (1) PT2029155E (hr)
RS (1) RS54928B1 (hr)
RU (1) RU2481853C2 (hr)
SI (1) SI2029155T1 (hr)
WO (1) WO2007101235A2 (hr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261104C2 (ru) * 1999-11-15 2005-09-27 Фарма Мар С.А. Лечение злокачественных опухолей аплидином
PL2029155T3 (pl) 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
WO2008135793A1 (en) * 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
EP2205263A1 (en) * 2007-10-19 2010-07-14 Pharma Mar, S.A. Improved antitumoral treatments
US20110015135A1 (en) * 2008-03-07 2011-01-20 Pharma Mar S.A. Antitumoral Treatments
CN101965191A (zh) * 2008-03-07 2011-02-02 法马马有限公司 改善的抗癌治疗
EP2851070A1 (en) * 2010-01-05 2015-03-25 Celgene Corporation A combination of lenalidomide and artesunate/artemisone for treating cancer
EP2786755A3 (en) * 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
WO2012075211A2 (en) * 2010-12-01 2012-06-07 Niiki Pharma Inc. Combination therapy with a gallium complex
BR112014011144A2 (pt) 2011-11-09 2017-05-16 Bristol Myers Squibb Co tratamento de malignidades hematológicas com um anticorpo anti-cxcr4
KR101369936B1 (ko) * 2011-12-28 2014-03-06 연세대학교 산학협력단 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물
RU2547999C1 (ru) * 2013-10-28 2015-04-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения аденогенного местно-распространенного рака нижнеампулярного отдела прямой кишки
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
EP3895733A4 (en) * 2018-12-14 2022-03-02 Konica Minolta, Inc. METHOD OF PREDICTING THE ARRIVAL OF A DRUG WITHIN DISEASED TISSUE
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
EP0220453B1 (de) 1985-09-20 1992-04-15 Cernitin S.A. Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
ATE321773T1 (de) 1996-10-24 2006-04-15 Univ Illinois Semisynthetisches verfahren zur herstellung von didemninanalogen
ATE245435T1 (de) 1996-10-24 2003-08-15 Univ Illinois Totalsynthese des amino hip analogen von didemnin a
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
CA2288639A1 (en) 1997-05-07 1998-11-12 Pharma Mar, S.A. Aplidine as an l-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
RU2266734C2 (ru) * 1999-05-13 2005-12-27 Фарма Мар, С.А. Композиции и применение ет743 для лечения злокачественных опухолей
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
RU2261104C2 (ru) * 1999-11-15 2005-09-27 Фарма Мар С.А. Лечение злокачественных опухолей аплидином
DK1276491T3 (da) 2000-04-07 2007-02-05 Univ Pennsylvania Tamandarin- og didemnin-analoger og fremgangsmåder til fremstilling og anvendelse af dem
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
RU2003113210A (ru) * 2000-10-12 2004-11-27 Фарма Мар, С.А. (Es) Лечение раковых заболеваний
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
US20040047807A1 (en) 2001-01-24 2004-03-11 Dominik Meyer Use of neurotoxic substances in producing a medicament for treating joint pains
EP1435991B1 (en) 2001-10-19 2008-10-15 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
MXPA05009742A (es) 2003-03-12 2006-05-25 Dana Farber Cancer Inst Inc Aplidina para tratamiento de mieloma multiple.
EP1613338A4 (en) 2003-03-21 2009-06-24 Madeleine M Joullie TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME
AU2004256425A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
PL2029155T3 (pl) 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
DE102006061344A1 (de) * 2006-12-22 2008-06-26 Robert Bosch Gmbh Kupplungshydraulikkreis
WO2008080956A1 (en) 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
WO2008135793A1 (en) 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
EP2205263A1 (en) 2007-10-19 2010-07-14 Pharma Mar, S.A. Improved antitumoral treatments
WO2010029158A1 (en) 2008-09-12 2010-03-18 Pharma Mar, S.A. Aplidine in the treatment of chronic myeloproliferative disorders

Also Published As

Publication number Publication date
AU2007220050A1 (en) 2007-09-07
RU2481853C2 (ru) 2013-05-20
CY1117722T1 (el) 2017-05-17
PT2029155E (pt) 2016-06-17
KR20140101014A (ko) 2014-08-18
NO342012B1 (no) 2018-03-12
JP2013199500A (ja) 2013-10-03
RU2008138560A (ru) 2010-04-10
NZ571043A (en) 2012-06-29
KR101512503B1 (ko) 2015-04-15
US8258098B2 (en) 2012-09-04
DK2029155T3 (en) 2016-08-01
CA2643238C (en) 2016-05-03
NO20084047L (no) 2008-11-25
PL2029155T3 (pl) 2016-09-30
EP2029155B1 (en) 2016-04-13
EP2029155A4 (en) 2009-10-14
SI2029155T1 (sl) 2016-06-30
CN101389347A (zh) 2009-03-18
ME02450B (me) 2016-09-20
US20090246168A1 (en) 2009-10-01
IL193094A0 (en) 2011-08-01
ES2575518T3 (es) 2016-06-29
CN101389347B (zh) 2013-03-27
AU2007220050B2 (en) 2013-08-29
RS54928B1 (sr) 2016-10-31
MX2008010999A (es) 2008-09-08
JP5393159B2 (ja) 2014-01-22
CA2643238A1 (en) 2007-09-07
HUE028055T2 (en) 2016-11-28
WO2007101235A2 (en) 2007-09-07
HK1127294A1 (zh) 2009-09-25
KR20080105123A (ko) 2008-12-03
WO2007101235A3 (en) 2008-04-03
EP2029155A2 (en) 2009-03-04
JP2009528379A (ja) 2009-08-06
IL193094A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
HRP20160646T1 (hr) Poboljšano liječenje multiplog mijeloma
TN2009000457A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
WO2012087976A3 (en) Novel inhibitors of hepatitis c virus replication
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
WO2007047146A3 (en) Inhibitors of viral replication
WO2009142842A3 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
WO2008005511A3 (en) Novel inhibitors of hepatitis c virus replication
WO2009048778A3 (en) Laminins, derivatives, and compositions including same and method for their therapeutic use
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
WO2009134616A3 (en) Novel inhibitors of hepatitis c virus replication
WO2009079451A3 (en) Compositions and methods of promoting wound healing
WO2010044585A3 (en) Piperidine compounds, pharmaceutical composition comprising the same and its use
IN2012MN02896A (hr)
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
MX2018008694A (es) Metodos y composiciones para tratar la hiperhidrosis.
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
MX2009005798A (es) Recuperacion de apoplejia.
NZ701133A (en) Composition for treating metabolic disorders
WO2012106058A3 (en) Animal treatments
WO2009155070A3 (en) Compositions and methods for treatment of inflammation and hyperkeratotic lesions
WO2009006246A8 (en) Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome